INTRA-IMMUSG PRIVATE LIMITED Report issue

For profit Phase 2
Founded: Singapore Singapore (2015)

Organization Overview

First Clinical Trial
2017
NCT03191682
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

INTRA-IMMUSG PRIVATE LIMITED | Intra-IMMUSG Pte Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

prl3-zumab (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1